2021
DOI: 10.37766/inplasy2021.5.0092
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta analysis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…The following inclusion criteria were used: (1) Chinese patients with BC; (2) cross-sectional, cohort or case-control studies; (3) studies reporting the prevalence or mean with standard deviation (SD); (4) validated methods, such as clinical interviews or selfreport instruments, used to assess anxiety or depression; (5) studied involving adults aged at least 18 years old; (6) Chinese literature published in core journal; and (7) studies with a sample size of no <5 (23). The following exclusion criteria were applied: (1) studies published in languages other than Chinese or English; (2) duplicated and useless data.…”
Section: Inclusion and Exclusion Criteriamentioning
confidence: 99%
“…The following inclusion criteria were used: (1) Chinese patients with BC; (2) cross-sectional, cohort or case-control studies; (3) studies reporting the prevalence or mean with standard deviation (SD); (4) validated methods, such as clinical interviews or selfreport instruments, used to assess anxiety or depression; (5) studied involving adults aged at least 18 years old; (6) Chinese literature published in core journal; and (7) studies with a sample size of no <5 (23). The following exclusion criteria were applied: (1) studies published in languages other than Chinese or English; (2) duplicated and useless data.…”
Section: Inclusion and Exclusion Criteriamentioning
confidence: 99%